Loading
Loading
Research Overview
Synthetic somatostatin octapeptide analogue; binds SSTR2 and SSTR5 receptors on pituitary somatotrophs and neuroendocrine cells to suppress GH release, glucagon, insulin, and gut hormone secretion — the mechanistic inverse of GH secretagogues.
Octreotide is a stable synthetic octapeptide analogue of somatostatin — the endogenous hormone that inhibits GH, glucagon, insulin, and various gut hormones. By binding SSTR2 and SSTR5 receptors preferentially, octreotide mimics somatostatin's inhibitory effects on the pituitary and pancreatic cells responsible for GH and gut hormone excess in disease states.
In acromegaly (GH excess from pituitary adenoma), octreotide suppresses GH and IGF-1 levels to near-normal ranges in approximately 60–70% of patients, reducing symptoms of growth hormone excess. In carcinoid syndrome and VIPomas, it suppresses the tumour-derived hormone overproduction causing flushing, diarrhoea, and other endocrine symptoms.
Octreotide is available in immediate-release (subcutaneous three times daily) and long-acting depot (intramuscular monthly) formulations. As an FDA-approved prescription medicine, it is obtained through specialist prescribers rather than research supply chains. Its mention in research contexts is primarily educational and comparative — understanding how somatostatin agonism contrasts with GH secretagogue mechanisms.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, octreotide (sandostatin) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Octreotide (Sandostatin) research is most relevant to protocols examining:
Acromegaly and GH excess treatment research
Carcinoid tumour and neuroendocrine tumour management studies
Somatostatin receptor (SSTR2/SSTR5) pharmacology research
GH suppression studies
mechanistic inverse of GH secretagogues
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~1.5 hours (IR); ~30 days (LAR)). Review data, confirm baseline recovery before any repeat protocol.
Synthetic somatostatin octapeptide analogue; binds SSTR2 and SSTR5 receptors on pituitary somatotrophs and neuroendocrine cells to suppress GH release, glucagon, insulin, and gut hormone secretion — the mechanistic inverse of GH secretagogues.
| Parameter | Value |
|---|---|
| Dose range | 50–200 mcg TID (IR) |
| Alt. dose 2 | 10–30 mg q4wk (LAR depot) |
| Schedule | Three times daily (IR) or monthly (LAR) |
| Route | Subcutaneous (IR), Intramuscular (LAR depot) |
| Half-life | ~1.5 hours (IR); ~30 days (LAR) |
nausea, diarrhoea, abdominal cramps (very common)
Insulin / oral hypoglycaemics: Octreotide suppresses both insulin AND glucagon
blood glucose regulation becomes unpredictable; monitor closely
Cyclosporine (immunosuppressant): Octreotide reduces cyclosporine absorption
lower blood levels, organ rejection risk in transplant patients
Bromocriptine: additive effects on GH suppression
rarely combined clinically
Beta-blockers
Octreotide can cause bradycardia; beta-blocker combination exacerbates this
Alcohol: masks symptoms of hypoglycaemia
dangerous when Octreotide is disrupting insulin/glucagon balance
Cocaine
severe cardiovascular risk with a compound already affecting heart rate and blood pressure
Cannabis
unpredictable appetite/GI interaction when Octreotide is already profoundly altering gut motility
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.